Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer

Inclusion Criteria: * Age: 18 to 75 years, Male or Female * Histological or cytologically diagnosis of non-small cell lung cancer * Recurrent or metastatic after surgical treatment * The pathology must be an assessable disease, signal lesion not exceeding 3 cm in diameter (measurable by CT scan or MRI)，number of Lymph node metastasis is less than 5 * Refractory to standard treatments (e.g., chemotherapy, radiation, etc.) * No chemotherapy and radiation therapy to be planned recently * Patients must have a Karnofsky performance status greater than or equal to 70% * Life expectancy greater than 3 months * Able and willing to give witnessed, written informed consent form prior to receiving any study related procedure * Agree that progress of the disease must be radiographically measurable by computerized tomography (CT) scanning technique or magnetic resonance imaging (MRI) (per RECIST1.1 criteria) * Agrees to participate in long-term follow-up for up to 3 years, if received NK and NKT infusion * Laboratory values within the following ranges prior to receiving treatment of study agent: Peripheral blood cells \>3×10\^9 /L; Number of lymphocytes \>1.0×10\^9 /L; Lymphocyte ratio \>18%; INR\<1.5. Exclusion Criteria: * Patients with no surgical treatment * Patients within concurrent chemotherapy or radiation * Known or suspected allergy to the investigational agent or any agent given in association with this trial * Negative HIV antigen and antibody, Hepatitis B surface antigen and Hepatitis C PCR within 21 days prior to enrollment * History of immunodeficiency disease or autoimmune disease * Patients with chronic disease which is undergoing immune reagents or hormone therapy * Serious infections requiring antibiotics, bleeding disorders * Previous bone marrow or stem cell transplant, or organ allograft * Concurrent other medical condition that would prevent the patient from undergoing protocol-based therapy * Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent * Pregnant or breast-feeding patients * Lack of availability of a patient for immunological and clinical follow-up